IRONWOOD PHARMACEUTICALS INC - Class A Common Stock (IRWD)

Historical Holders from Q1 2014 to Q3 2025

Symbol
IRWD on Nasdaq
Type / Class
Equity / Class A Common Stock
Shares outstanding
162M
All holders as of 30 Sep 2025
Q3 2025
Total 13F shares, excl. options
149M
Holdings value
$195M
% of all portfolios
0%
Grand Portfolio weight change
+0%
Number of holders
161
Number of buys
78
Number of sells
-65
Average Value change %
0%
Average buys %
+0%
Average sells %
0%
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of IRONWOOD PHARMACEUTICALS INC - Class A Common Stock (IRWD)

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
VANGUARD GROUP INC 10.01% +2.1% $10.9M $339K 16.2M +3.22% The Vanguard Group 30 Jun 2025
ARMISTICE CAPITAL, LLC 8.47% +42.5% $12.1M $3.72M 13.7M +44.7% Armistice Capital, LLC 31 Mar 2025
BANK OF AMERICA CORP /DE/ 7.4% $15.7M 12M BANK OF AMERICA CORP /DE/ 30 Sep 2025
BlackRock, Inc. 7.1% $9.93M 11.3M BlackRock, Inc. 28 Feb 2025
RENAISSANCE TECHNOLOGIES LLC 5.37% $7.57M 8.6M Renaissance Technologies LLC 15 May 2024
STATE STREET CORP 2.2% -60% $3.08M -$4.25M 3.5M -58% STATE STREET CORPORATION 31 Mar 2025
BARCLAYS PLC 1.95% -70.4% $4.15M -$10.4M 3.17M -71.5% Barclays PLC 30 Sep 2025
Pacer Advisors, Inc. 1.12% -88.6% $1.57M -$8.75M 1.79M -84.7% Pacer US Small Cap Cash Cows ETF 31 Mar 2025

Institutional Holders of IRONWOOD PHARMACEUTICALS INC - Class A Common Stock (IRWD)

Period Reported Shares, Excl. Options Value, Excl. Options Change Price Investors
2025 Q3 149M $195M +$6.27M $1.31 161
2025 Q2 146M $105M -$20M $0.72 151
2025 Q1 156M $229M -$26M $1.47 200
2024 Q4 164M $727M +$1.74M $4.43 222
2024 Q3 163M $673M -$53.2M $4.12 218
2024 Q2 171M $1.12B -$10.4M $6.52 226
2024 Q1 172M $1.5B +$34.5M $8.71 259
2023 Q4 165M $1.89B +$27.5M $11.44 248
2023 Q3 162M $1.56B -$47.8M $9.63 248
2023 Q2 166M $1.77B +$4.55M $10.64 249
2023 Q1 165M $1.74B -$25.4M $10.52 253
2022 Q4 168M $2.08B -$12M $12.39 248
2022 Q3 170M $1.76B -$66.9M $10.36 234
2022 Q2 175M $2.02B +$105M $11.53 229
2022 Q1 167M $2.09B -$62.7M $12.58 205
2021 Q4 172M $2B -$78.2M $11.66 206
2021 Q3 177M $2.32B +$38.2M $13.06 216
2021 Q2 175M $2.25B +$54.4M $12.87 200
2021 Q1 171M $1.91B -$10.3M $11.18 202
2020 Q4 172M $1.95B -$290K $11.39 191
2020 Q3 179M $1.61B -$60M $9.00 183
2020 Q2 178M $1.84B +$1.17M $10.32 196
2020 Q1 179M $1.8B +$4.16M $10.09 186
2019 Q4 177M $2.36B +$49.4M $13.31 191
2019 Q3 174M $1.49B +$101M $8.59 156
2019 Q2 161M $1.76B +$57.8M $10.94 148
2019 Q1 155M $2.09B +$91.1M $13.53 150
2018 Q4 150M $1.55B -$71.2M $10.36 141
2018 Q3 145M $2.67B -$61M $18.46 149
2018 Q2 149M $2.85B -$59.8M $19.12 145
2018 Q1 152M $2.35B -$1.01M $15.43 145
2017 Q4 153M $2.29B -$72.5M $14.99 157
2017 Q3 157M $2.48B +$151M $15.77 145
2017 Q2 148M $2.78B +$174M $18.88 165
2017 Q1 146M $2.5B +$313M $17.06 158
2016 Q4 140M $2.14B +$7.06M $15.29 159
2016 Q3 138M $2.19B +$19.2M $15.88 150
2016 Q2 137M $1.79B -$46.6M $13.07 142
2016 Q1 141M $1.54B +$6.58M $10.94 133
2015 Q4 140M $1.62B -$10M $11.59 133
2015 Q3 141M $1.47B -$31.6M $10.42 129
2015 Q2 144M $1.73B +$111M $12.06 137
2015 Q1 134M $2.14B +$8.24M $16.00 142
2014 Q4 134M $2.05B +$20.1M $15.32 129
2014 Q3 132M $1.71B +$65.7M $12.96 138
2014 Q2 126M $1.93B -$76.7M $15.33 136
2014 Q1 132M $1.62B +$224M $12.32 135